BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
2 March 2021

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse